Inhibrx Biosciences, Inc. (Nasdaq: INBX) announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, revealing a significant reduction in net losses compared to the previous year. The company reported a net loss of $32.8 million for the fourth quarter of 2025, or $2.11 per share, down from a net loss of $47.9 million, or $3.09 per share, in the same quarter of 2024. For the entire fiscal year 2025, Inhibrx recorded a net loss of $140.1 million, a stark contrast to a net income of $1.7 billion in 2024, which was largely attributed to the completion of the 101 Transaction with Sanofi S.A. The company highlighted that its cash and cash equivalents stood at $124.2 million as of December 31, 2025, bolstered by a recent $75 million loan agreement with Oxford Finance, LLC. Inhibrx is currently advancing two clinical programs, with plans to submit a Biologics License Application for its lead candidate, ozekibart, in the second quarter of 2026. The company also anticipates announcing key clinical data in the upcoming months, which could further influence its operational trajectory and market position.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.